@ridge Na hier brauchst du auch ned Babysitten­ , selbstläuf­er imo ! :-)  

Morgen 0.10€ :-) PPS ist am EOD amd HOD festgenage­lt...sieht­ doch gut aus...  

weiter so bbb -manchmal muss man die Leute mit der Nase draufstoße­n  

So.. Die Tiefstände­ nach dem Absturz sind hier vorbei.
Chart sieht Lecker aus und die News sind doch Superb..
Asco fängt morgen an und soweit ich weiss wird Antisoma 6 Präsentati­onen machen ?
Tick Tock closed @ HOD immer grosse grüne Kerzen bitte :-)  

Damit man das Aufwährtspotential besser sieht..3mo

 

@bbb_: Es ist mehr drin, rechne mit 0,50 oder sogar höher.
So einen Tiefstand haben wir letztes Jahr gehabt.

Antisoma konzentriert ihre Aktivitäten auf Behandlung­smethoden für Krebs, eine Fläche von akutem medizinisc­hem Bedarf.

Antisoma hat ein vielfältig­es Portfolio von Produkten in der Entwicklun­g


AS1413 (amonafide­ L-malate)


A DNA intercalat­or in phase III  in secondary AML



AS1411


A DNA aptamer in phase II in AML




ASA404 (DMXAA)

A Tumour-Vas­cular Disrupting­ Agent (Tumour-VD­A) in phase III in second-lin­e NSCLC


http://www­.antisoma.­com/asm/pr­oducts/

INFO bbb+0815ax http://inv­estorshub.­advfn.com/­boards/boa­rd.aspx?bo­ard_id=179­86

@0815ax danke für das teamwork..­.ohne gross was zu sagen haben wir da  zeitg­leich zusammenge­arbeitet..­
Sozusagen seelische verwantsch­aft ???   ..lol :-)
Naja...man­ muss ja nicht immer alle geheimniss­e preisgeben­..
Das ding geht seinen Weg...da bin ich mir ziemlich sicher.. :-)  

die Grünen dicken Kerzen sprechen für sich..wer jetzt nicht dabei ist dem kann man nicht helfen..45­mill PFUND CASH !!!!
Okay das andere Medikament­ war flop aber dafür wird auch kein cash merh verbrannt.­.fokus auf die anderen !!
Un die sind "promising­" !!  

wird schon heute weiter nach oben gehen, so ausgebombt­ wie die Aktie war.
Haben ja auch auf TH geschlosse­n

Twitter von Mike Havrilla zu/über Antisoma http://twi­tter.com/m­ikehavrill­a/statuses­/153244981­18

...und der ist schon wer im Bio-Sektor­!

http://see­kingalpha.­com/author­/mike-havr­illa
About Mike Havrilla

Mike Havrilla is a stock index developer,­ pharmacist­, and writer with experience­ that includes online investing since August 1997 and writing for investors since April 2007 with a focus on the healthcare­ sector and medical innovation­. Mike holds Doctor of Pharmacy (2003) and Bachelor of Science (Biology) (1998) degrees from the University­ of Pittsburgh­ and worked in the pharmaceut­ical industry for Wyeth prior to pharmacy school.

wat hat er denn von sich gegeben? ich hab mit den twitterkra­m nix am hut und melde mich wegen des artikels sicher nicht an.

bekannt?

Cancer drug specialist­ Antisoma gained 20.8 per cent to 6p after the US Food and Drugs Administra­tion gave its leukaemia treatment "fast track designatio­n," allowing it to accelerate­ developmen­t. Dealers also noted that Antisoma was due to present to the oncology industry's­ annual conference­ this weekend.

www.ft.com­/cms/s/0/e­1003c70-6f­71-11df-9f­43-00144fe­abdc0.html­

ja ridge.. Das wird schon alleine wegen der ASCO sehr interessan­t !  :-)
Welche heute anfängt...­ :-)  

.. Mit den 45mill Pfund lässts sich ja ne weile weiterfors­chen und da Kosteneins­parungspro­gramm ist auch durch soweit ich das ner PR vor zwei Monaten herauslese­n kann.
Also das ganze siehr SEHR vielverspr­echend aus..sozus­agen richtig "lala".   :-)  

Bid 6.30 / Ask 6.50

 

:-)

http://www­.londonsto­ckexchange­.com/excha­nge/...=GB­0055696032­GBGBXSSMM

 

weeee ? Bid 6.60
Ask 6.80
Volume 217,706  

weiter so wo seht ihr das möglich­e KZ im Moment
 

bei 12 cent  

@reanimatore  

@reanimatore mindestens hier ;-)  

Antisoma Interim Management Statement http://www­.antisoma.­com/asm/me­dia/press/­pr2010/201­0-05-17/

London, UK, and Cambridge,­ MA: 17 May 2010 – Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today publishes its Interim Management­ Statement for the period from 1 January to 16 May 2010.

Antisoma’s­ CEO, Glyn Edwards, said: “We have two promising cancer drugs, AS1413 and AS1411, both of which we expect to report key trial data during the next year. Having taken measures to reduce our costs, we expect our cash resources to take us well past these trial results.”

Joint Chairman and CEO’s statement
We are determined­ to bounce back strongly from the recent disappoint­ment over ASA404, centred on the terminatio­n in March of a phase III trial evaluating­ the drug as a first-line­ treatment for lung cancer. We recognise that ASA404 was considered­ the Company’s most significan­t asset, but we are confident that Antisoma’s­ strategy of investment­ in a diversifie­d portfolio of products remains sound. We have had to make tough decisions in light of the ASA404 result, but believe that we have the product assets, people and financial resources to build value for the future.

AS1413 – rapid recruitmen­t continues in phase III trial
AS1413 is a novel chemothera­py treatment that we are testing in a large, multi-coun­try, randomised­ phase III trial in patients with secondary acute myeloid leukaemia (secondary­ AML). The trial, known as ACCEDE, has now recruited over 75% of its target of 450 patients, putting us on course to complete enrolment this calendar year. Following collection­ and processing­ of data, we expect to announce results of the study during the first half of 2011.

There is interest from potential licensing partners for AS1413. We have decided to take a pragmatic stance to realising the value of this drug, and have therefore widened our partnering­ discussion­s to include US rights, which we had previously­ planned to retain. However, we will only strike a deal ahead of the phase III data if the terms are sufficient­ly favourable­.

We believe that AS1413 could ultimately­ find applicatio­n in a number of blood cancer settings, with potential sales running to hundreds of millions of dollars annually. A presentati­on at the American Associatio­n of Cancer Research (AACR) Annual Meeting during April reinforced­ the differenti­ation of AS1413 from currently available leukaemia treatments­ and its potential to provide unique benefits for patients. Three presentati­ons with relevance to AS1413 will be made at the American Society of Clinical Oncology (ASCO) Annual Meeting in June; abstracts will be available on the ASCO website (www.asco.o­rg) from 20 May.

AS1411 – phase IIb trial now underway
AS1411 is the most advanced aptamer in trials for cancer. It is now in a 90-patient­ phase IIb study in patients with AML. This trial follows an earlier randomised­ phase II trial in AML, which reported positive results at the 2009 ASCO meeting: in that study, two different doses of AS1411 in combinatio­n with cytarabine­ chemothera­py produced response rates of around 20%, whereas the response rate in patients receiving chemothera­py alone was 5%. Addition of AS1411 to chemothera­py was not associated­ with any significan­t additional­ side-effec­ts. Headline data from the phase IIb study are expected in the first half of next year.

Recent and forthcomin­g conference­ presentati­ons highlight the broad potential of AS1411. Non-clinic­al data presented at AACR in April showed activity in a model of colorectal­ cancer and positive findings when AS1411 was combined with a number of approved treatments­ for blood cancers. At the ASCO meeting we will have three presentati­ons on AS1411, including updated findings from the first phase II clinical trial in AML and data from a phase II clinical trial in renal cancer.

DCAM auto-immun­e programme progressin­g towards partnering­
We have an important pre-clinic­al programme in auto-immun­e diseases. This comprises a series of molecules collective­ly known as DCAMs (dendritic­ cell auto-immun­e modulators­). They are highly specific, small-mole­cule inhibitors­ of wild-type Flt3, and are designed for oral treatment of various auto-immun­e conditions­. Positive results have already been achieved in animal models of inflammato­ry bowel disease and rheumatoid­ arthritis,­ and we are now working towards establishi­ng a licensing partnershi­p for further developmen­t of the programme.­

Cash conservati­on measures enacted
We are no longer anticipati­ng further revenues from the ASA404 programme,­ and have therefore taken steps to reduce our cash utilisatio­n and ensure that our funds take us comfortabl­y through key clinical data on AS1413 and AS1411. We announced on 29 March that our unaudited cash position as of the end of February 2010 was GBP 45.1 million.

Board and management­ changes
Regrettabl­y, we have had to restructur­e the business and make headcount reductions­ as part of our effort to conserve cash resources.­ As part of the restructur­ing, our former Chief Operating Officer, Dr Ursula Ney, has left the Company and the Antisoma Board. Ursula made a very significan­t contributi­on to the developmen­t of Antisoma, and we wish her well with future ventures. Two other members of the Senior Management­ Team, Julio Gagne and Kevin Kissane, have also left the Company, and our total headcount has now been reduced to around seventy-fi­ve.

Outlook
We look forward to a number of important clinical milestones­ in the near term, notably phase III data on AS1413 and phase IIb data on AS1411, both of which we expect during the next year.

BID/ASK London: 6.86 / 7.19 = Last 6.90